glycoprotein

(redirected from P-glycoprotein)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to P-glycoprotein: ABCB1

gly·co·pro·tein

 (glī′kō-prō′tēn′, -tē-ĭn)
n.
Any of a group of conjugated proteins having a carbohydrate as the nonprotein component.

glycoprotein

(ˌɡlaɪkəʊˈprəʊtiːn) ,

glucoprotein

or

glycopeptide

n
(Biochemistry) any of a group of conjugated proteins containing small amounts of carbohydrates as prosthetic groups. See also mucoprotein

gly•co•pro•tein

(ˌglaɪ koʊˈproʊ tin, -ti ɪn)

n.
any of a group of complex proteins, as mucin, containing a carbohydrate combined with a simple protein.
Also called gly`co•pep′tide (-ˈpɛp taɪd)
[1905–10]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.glycoprotein - a conjugated protein having a carbohydrate component
mucin - a nitrogenous substance found in mucous secretions; a lubricant that protects body surfaces
compound protein, conjugated protein - a protein complex combining amino acids with other substances
erythropoietin - a glycoprotein secreted by the kidneys that stimulates the production of red blood cells
CD4, cluster of differentiation 4 - a glycoprotein that is found primarily on the surface of helper T cells; "CD4 is a receptor for HIV in humans"
CD8, cluster of differentiation 8 - a membrane glycoprotein that is found primarily on the surface of cytotoxic T cells
lectin - any of several plant glycoproteins that act like specific antibodies but are not antibodies in that they are not evoked by an antigenic stimulus
mucoid - any of several glycoproteins similar to mucin
References in periodicals archive ?
ATP-dependent anticancer drug efflux by P-glycoprotein (Pgp) (Bellamy 1996; Gottesman et al.
Patients were dose reduced for creatinine clearance (CrCL) 30 to 50 mL/min, body weight of 60 kg or less or certain p-glycoprotein inhibitor use.
The P-glycoprotein molecule is a drug transport pump that plays an important role in limiting drug absorption and distribution (particularly to the brain) and enhancing the excretion/elimination of many drugs used in dogs.
For example, amiodarone and verapamil, which are used to treat the underlying rhythm disturbance in atrial fibrillation, inhibit intestinal P-glycoprotein so that increased amounts of dabigatran are absorbed (Lehne, 2013).
Patients will be randomized to receive edoxaban 60 mg (or a patient specific dose of edoxaban 30 mg for patients with renal impairment or low body weight or p-glycoprotein inhibitor use) or enoxaparin/warfarin for 28-49 days.
To evaluate the stability of DHLA-coated QDs in culture media and the specificity of labeling live cells with these QDs, we used P-glycoprotein (Pgp)--a cell surface multidrug transporter protein that provides chemoresistance to tumor cells.
Digoxin drug interactions involving the transporter P-glycoprotein are also possible.
The experimental treatment method allows small therapeutic agents to safely cross the blood-brain barrier in laboratory rats by turning off P-glycoprotein, one of the main gatekeepers preventing medicinal drugs from reaching their intended targets in the brain.
This study was made in a genetically-modified cell model of the blood-brain barrier that contains high levels of the transporter P-glycoprotein.
Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukemia cells predict a poor response to chemotherapy and reduced patient survival.
In cancer cells, ABC transporters such as P-glycoprotein (P-gp; MDR1, ABCB1), breast cancer resistance protein (BCRP; ABCG2), and multidrug resistance protein 2 (MRP2; ABCC2), eliminate intracellular drug load by transporting substrates (including anthracyclines and taxanes) across the plasma membrane and out of the cell--preventing anti-cancer drugs from reaching their cellular targets [4,5].
Among their topics are using genetically engineered mouse models to study drug resistance in breast cancer, the flow cytometric evaluation of multidrug resistance proteins, drug ration- dependent antagonism as a new category of multidrug resistance and strategies for its circumvention, pharmaco-kinetic and pharmaco-dynamic implications of P-glycoprotein modulation, immuno-suppressors as multidrug resistance reversal agents, and overcoming multidrug resistance by RNA interference.